A randomised, double blind, placebo controlled, phase II study of fulvestrant with or without the addition of vandetanib as treatment for patients with metastatic breast cancer resistant to aromatase inhibitor therapy.

Trial Profile

A randomised, double blind, placebo controlled, phase II study of fulvestrant with or without the addition of vandetanib as treatment for patients with metastatic breast cancer resistant to aromatase inhibitor therapy.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Fulvestrant (Primary) ; Vandetanib (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms FURVA
  • Most Recent Events

    • 22 Jan 2016 Status changed from recruiting to active, no longer recruiting.
    • 05 Dec 2015 Accrual to date is 16% according to United Kingdom Clinical Research Network record.
    • 04 Nov 2015 Accrual to date is 13% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top